Boston Scientific Corporation is scheduled to participate in the Wells Fargo Healthcare Conference on June 24th in Boston.
-
Pages
-
Categories
-
Archives
Boston Scientific Corporation is scheduled to participate in the Wells Fargo Healthcare Conference on June 24th in Boston.
Boston Scientific Corporation recently launched the TAXUS Element Paclitaxel-Eluting Coronary Stent System in the European Union and other CE Mark countries.
Boston Scientific Corp.s Taxus Element Stent System has launched in the European market and been implanted in its first European patients, the Natick-based medical devices giant announced today.
Boston Scientific Corporation (NYSE: BSX) ha anunciado hoy el lanzamiento al mercado y el primer implante de su stent coronario liberador de paclitaxel, TAXUS(R) Element(TM) en la Unión Europea y en otros países de aplicación del marcado CE. TAXUS Element constituye la tecnología de tercera generación de la empresa en stents farmacoactivos e incorpora una aleación de cromo-platino junto a un …
Boston Scientific Corporation (NYSE: BSX) hat heute die Markteinführung und die ersten Implantationen seines Paclitaxel freisetzenden Koronarstentsystems TAXUS(R) Element(TM) in den Staaten der Europäischen Union sowie weiteren Ländern, in denen die CE-Zertifizierung gilt, bekannt gegeben.
Boston Scientific Corporation announced CE Mark and US Food and Drug Administration (FDA) approval of its NC Quantum Apex PTCA Dilatation Balloon Catheter. The company plans to launch the product in European markets this week and in the US next month.
NATICK, Mass., May 26 /PRNewswire-FirstCall/ — Boston Scientific Corporation (NYSE: BSX) today announced the initiation of the PLATINUM PLUS clinical trial, an investigator-sponsored research (ISR) study designed to compare the performance of the PROMUS(®) Element(TM) Everolimus-Eluting Coronary Stent System to the XIENCE PRIME(TM) Everolimus-Eluting Coronary Stent System.
Boston Scientific Corp. (BSX) said Wednesday that it has initiated the Platinum Plus clinical trial designed to compare performance of its Promus Element Everolimus-Eluting Coronary Stent System with Abbott Laboratories (ABT) Xience Prime Everolimus-Eluting Coronary Stent System.